Developer docs
API playgroundTry for free, no card

Search company profiles

Pharos iBio Co.

Full company profile

uuid0002vep

Namestring
Pharos iBio Co.
Websiteurl
pharosibio.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Pharos iBio Co. is a South Korea-based, KOSDAQ-listed (388870) AI-driven drug discovery company founded in 2016, headquartered in Anyang, with an 11-50 employee team focused on developing therapeutics for intractable diseases. The company builds and operates the Chemiverse platform, which combines proprietary drug discovery expertise with AI/ML predictive systems to identify and validate drug candidates. Its commercial posture is partnership-led, serving global pharmaceutical companies through AI services and platform collaboration arrangements; revenue is generated via AI drug development services and licensing/royalty structures tied to its proprietary platform, although pricing is not publicly disclosed.

The company's core technical differentiator is its integration with Eli Lilly's TuneLab AI platform via NVIDIA FLARE federated learning — the first such integration by a Korean AI drug discovery firm. This architecture enables collaborative model training across organizational boundaries without sharing raw molecular data, addressing pharmaceutical industry data privacy constraints. Chemiverse handles structured molecular and drug development data, supports multimodal AI workloads, and incorporates generative AI for candidate generation and predictive analytics for candidate validation. Distribution is via direct enterprise field sales to global pharma, augmented by conference-based partnering (e.g., BIO USA 2026).

Operationally, Pharos iBio has raised roughly 55 million USD cumulatively across five funding rounds between 2018 and 2025, led by Korean institutional investors including Company K Partners, Korea Investment Partners, and Korea Investment & Securities. The company completed a KOSDAQ listing (announced 2022 H2), and a 14% stock-price move in January 2026 reflected sector tailwinds from Insilico Medicine's Hong Kong listing. Management team composition, leadership hires, and granular revenue figures are not disclosed in available sources, and disclosed financials in the input carry unit/currency inconsistencies that limit revenue triangulation precision.

Short descriptiontext

Pharos iBio is a KOSDAQ-listed South Korean AI drug discovery company that uses its proprietary Chemiverse platform and federated learning (NVIDIA FLARE) to develop therapeutics for intractable diseases, serving global pharmaceutical partners such as Eli Lilly through licensing and AI development services.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersAnyang, South Korea
HQ citystring
Anyang
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Keyword5 values
AI drug discovery, drug development services, pharmaceutical AI platform, federated learning healthcare, computational drug discovery
Industry2 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
AI Drug Discovery Platform
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1AI Drug Development Services
TypeSubscription Recurring
Description

The company generates revenue through AI-powered new drug development services, providing pharmaceutical companies with AI/ML-driven drug discovery and development capabilities.

v.daum.net
2Platform Collaboration Licensing
TypeLicensing Royalties
Description

Revenue generated through strategic partnerships with major pharmaceutical companies, integrating proprietary Chemiverse platform with partners' AI systems for drug candidate validation.

ajupress.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Pharos iBio is a pharmaceutical company that develops drugs for intractable diseases using its proprietary Chemiverse AI platform, which combines in-house drug development expertise with AI/ML predictive systems. The company delivers AI-powered new drug development services and collaborates with global pharmaceutical firms to validate drug candidates and accelerate discovery timelines.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Stock price surged 14% in January 2026 amid positive AI drug development sentiment following Insilico Medicine's Hong Kong IPO success
Product overview1 text field

Pharos iBio Co. operates as an AI-driven new drug development company offering a single integrated platform (Chemiverse) that combines the company's proprietary drug development expertise with external AI/ML predictive systems. The Chemiverse platform serves as the core technology offering, enabling drug candidate validation and collaboration with global pharmaceutical partners like Eli Lilly through integration with Lilly TuneLab.

Product and service2 records
1Chemiverse Platform
CategoryAI drug development platform
Description

Proprietary AI drug development platform that integrates Pharos iBio's drug development expertise with AI/ML predictive systems. It enables validation of drug candidates and collaboration with global pharmaceutical partners, including integration with Eli Lilly's Lilly TuneLab platform.

2AI-Powered New Drug Development Services
CategoryDrug development services
Description

Service offering that applies AI/ML-driven drug discovery and development capabilities to pharmaceutical partners, accelerating drug discovery timelines and reducing R&D costs for intractable disease targets.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-09
Description

Pharos iBio signed a strategic cooperation agreement with Eli Lilly on June 9, 2026, to collaborate on Lilly TuneLab, Eli Lilly's AI drug development platform using federated learning technology based on NVIDIA FLARE. The partnership enables Pharos iBio to integrate its Chemiverse platform and drug development expertise with Eli Lilly's AI/ML predictive systems, marking the first domestic AI drug development firm to connect with Lilly TuneLab. Through this collaboration, Pharos iBio aims to validate drug candidates and enhance platform capabilities to strengthen global competitiveness.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-driven drug discovery company that recently completed a successful Hong Kong IPO. Directly comparable to Pharos iBio as a pure-play AI drug discovery platform targeting intractable diseases, and is the explicit market catalyst cited in Pharos's January 2026 stock surge.

TypeDirect peer
Description

AI-driven drug discovery platform combining high-throughput biology with machine learning to identify novel therapeutics. Comparable to Pharos in using AI/ML predictive systems to accelerate drug candidate identification and validation, with a similar platform-partnering GTM motion.

TypeDirect peer
Description

Physics-based computational platform for drug discovery and materials science. Highly comparable as a software-plus-services AI drug discovery platform that licenses its predictive platform to global pharmaceutical companies, mirroring Pharos's Chemiverse licensing model.

TypeDirect peer
Description

AI-driven precision medicine company focused on small molecule drug discovery. Comparable to Pharos in offering AI drug discovery services to pharma partners and pursuing a similar partner-centric commercial model.

TypeDirect peer
Description

AI-powered drug discovery company combining quantum physics, AI, and robotics. Highly comparable as an Asia-based AI drug discovery platform pursuing global pharmaceutical partnerships and licensing arrangements, sharing Pharos's geographic positioning and GTM motion.

TypeDirect peer
Description

AI-driven small molecule drug discovery company using structure-based deep learning. Comparable to Pharos as an AI drug discovery platform that partners with global pharma on candidate validation and licensing.

TypeDirect peer
Description

AI-driven drug discovery company applying machine learning to biomedical knowledge graphs. Comparable to Pharos in offering AI drug discovery capabilities to global pharmaceutical partners targeting complex diseases.

8Isomorphic Labs
TypeDirect peer
Description

Alphabet-owned AI drug discovery company leveraging DeepMind's AlphaFold technology. Comparable as a deep-tech AI drug discovery platform pursuing partnerships with major pharmaceutical companies for candidate development.

TypeBroad incumbent
Description

Global pharmaceutical company and Pharos iBio's flagship TuneLab integration partner. Comparable as a strategic customer and platform partner — Lilly's TuneLab federated learning platform defines the integration architecture that Pharos's Chemiverse connects into.

TypeEmerging player
Description

AI-driven drug discovery company focused on complex diseases using causal machine learning. Comparable to Pharos as a smaller, emerging AI drug discovery platform pursuing pharma partnerships and targeting intractable therapeutic areas.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pharos iBio Co.

AI Drug Discovery Platformpharosibio.com

Pharos iBio is a KOSDAQ-listed South Korean AI drug discovery company that uses its proprietary Chemiverse platform and federated learning (NVIDIA FLARE) to develop therapeutics for intractable diseases, serving global pharmaceutical partners such as Eli Lilly through licensing and AI development services.

What Pharos iBio Co. does

Pharos iBio Co. is a South Korea-based, KOSDAQ-listed (388870) AI-driven drug discovery company founded in 2016, headquartered in Anyang, with an 11-50 employee team focused on developing therapeutics for intractable diseases. The company builds and operates the Chemiverse platform, which combines proprietary drug discovery expertise with AI/ML predictive systems to identify and validate drug candidates. Its commercial posture is partnership-led, serving global pharmaceutical companies through AI services and platform collaboration arrangements; revenue is generated via AI drug development services and licensing/royalty structures tied to its proprietary platform, although pricing is not publicly disclosed.

The company's core technical differentiator is its integration with Eli Lilly's TuneLab AI platform via NVIDIA FLARE federated learning — the first such integration by a Korean AI drug discovery firm. This architecture enables collaborative model training across organizational boundaries without sharing raw molecular data, addressing pharmaceutical industry data privacy constraints. Chemiverse handles structured molecular and drug development data, supports multimodal AI workloads, and incorporates generative AI for candidate generation and predictive analytics for candidate validation. Distribution is via direct enterprise field sales to global pharma, augmented by conference-based partnering (e.g., BIO USA 2026).

Operationally, Pharos iBio has raised roughly 55 million USD cumulatively across five funding rounds between 2018 and 2025, led by Korean institutional investors including Company K Partners, Korea Investment Partners, and Korea Investment & Securities. The company completed a KOSDAQ listing (announced 2022 H2), and a 14% stock-price move in January 2026 reflected sector tailwinds from Insilico Medicine's Hong Kong listing. Management team composition, leadership hires, and granular revenue figures are not disclosed in available sources, and disclosed financials in the input carry unit/currency inconsistencies that limit revenue triangulation precision.

Pharos iBio Co. firmographics

Firmographics
Name
Pharos iBio Co.
Website
https://pharosibio.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
Pharos iBio is a KOSDAQ-listed South Korean AI drug discovery company that uses its proprietary Chemiverse platform and federated learning (NVIDIA FLARE) to develop therapeutics for intractable diseases, serving global pharmaceutical partners such as Eli Lilly through licensing and AI development services.
Ownership category
akta.pro rank

Pharos iBio Co. industry classification

Industry
Product category
AI Drug Discovery Platform
NAICS
Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)

Keywords

  • AI drug discovery
  • Drug development services
  • Pharmaceutical AI platform
  • Federated learning healthcare
  • Computational drug discovery

Where Pharos iBio Co. is headquartered

Location

Headquarters

HQ city
Anyang
HQ country
South Korea
HQ region
Asia

Markets served

Pharos iBio Co. business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales

Revenue model

  1. AI Drug Development Services: The company generates revenue through AI-powered new drug development services, providing pharmaceutical companies with AI/ML-driven drug discovery and development capabilities.
  2. Platform Collaboration Licensing: Revenue generated through strategic partnerships with major pharmaceutical companies, integrating proprietary Chemiverse platform with partners' AI systems for drug candidate validation.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels2 records

Pharos iBio Co. product offering

Product offering

Core offering

Pharos iBio is a pharmaceutical company that develops drugs for intractable diseases using its proprietary Chemiverse AI platform, which combines in-house drug development expertise with AI/ML predictive systems. The company delivers AI-powered new drug development services and collaborates with global pharmaceutical firms to validate drug candidates and accelerate discovery timelines.

Product overview

Pharos iBio Co. operates as an AI-driven new drug development company offering a single integrated platform (Chemiverse) that combines the company's proprietary drug development expertise with external AI/ML predictive systems. The Chemiverse platform serves as the core technology offering, enabling drug candidate validation and collaboration with global pharmaceutical partners like Eli Lilly through integration with Lilly TuneLab.

Differentiator

Problem solved

Functional benefit

Products and services

  • Chemiverse Platform Proprietary AI drug development platform that integrates Pharos iBio's drug development expertise with AI/ML predictive systems. It enables validation of drug candidates and collaboration with global pharmaceutical partners, including integration with Eli Lilly's Lilly TuneLab platform.
  • AI-Powered New Drug Development Services Service offering that applies AI/ML-driven drug discovery and development capabilities to pharmaceutical partners, accelerating drug discovery timelines and reducing R&D costs for intractable disease targets.

Quantifiable outcome

  • Stock price surged 14% in January 2026 amid positive AI drug development sentiment following Insilico Medicine's Hong Kong IPO success

Companies that use Pharos iBio Co.

Customer profile

Segments2 records

Ideal customer profiles2 records

Pharos iBio Co. technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability4 records

Feature2 records

Pharos iBio Co. partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Eli LillycoreStrategic or Co-development Partner · 9 June 2026Pharos iBio signed a strategic cooperation agreement with Eli Lilly on June 9, 2026, to collaborate on Lilly TuneLab, Eli Lilly's AI drug development platform using federated learning technology based on NVIDIA FLARE. The partnership enables Pharos iBio to integrate its Chemiverse platform and drug development expertise with Eli Lilly's AI/ML predictive systems, marking the first domestic AI drug development firm to connect with Lilly TuneLab. Through this collaboration, Pharos iBio aims to validate drug candidates and enhance platform capabilities to strengthen global competitiveness.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Pharos iBio Co. competitors and assessment

Company assessment

Direct peers

  • Insilico Medicine: AI-driven drug discovery company that recently completed a successful Hong Kong IPO. Directly comparable to Pharos iBio as a pure-play AI drug discovery platform targeting intractable diseases, and is the explicit market catalyst cited in Pharos's January 2026 stock surge.
  • Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput biology with machine learning to identify novel therapeutics. Comparable to Pharos in using AI/ML predictive systems to accelerate drug candidate identification and validation, with a similar platform-partnering GTM motion.
  • Schrödinger: Physics-based computational platform for drug discovery and materials science. Highly comparable as a software-plus-services AI drug discovery platform that licenses its predictive platform to global pharmaceutical companies, mirroring Pharos's Chemiverse licensing model.
  • Exscientia: AI-driven precision medicine company focused on small molecule drug discovery. Comparable to Pharos in offering AI drug discovery services to pharma partners and pursuing a similar partner-centric commercial model.
  • XtalPi: AI-powered drug discovery company combining quantum physics, AI, and robotics. Highly comparable as an Asia-based AI drug discovery platform pursuing global pharmaceutical partnerships and licensing arrangements, sharing Pharos's geographic positioning and GTM motion.
  • Atomwise: AI-driven small molecule drug discovery company using structure-based deep learning. Comparable to Pharos as an AI drug discovery platform that partners with global pharma on candidate validation and licensing.
  • BenevolentAI: AI-driven drug discovery company applying machine learning to biomedical knowledge graphs. Comparable to Pharos in offering AI drug discovery capabilities to global pharmaceutical partners targeting complex diseases.
  • Isomorphic Labs: Alphabet-owned AI drug discovery company leveraging DeepMind's AlphaFold technology. Comparable as a deep-tech AI drug discovery platform pursuing partnerships with major pharmaceutical companies for candidate development.

Broad incumbents

  • Eli Lilly: Global pharmaceutical company and Pharos iBio's flagship TuneLab integration partner. Comparable as a strategic customer and platform partner — Lilly's TuneLab federated learning platform defines the integration architecture that Pharos's Chemiverse connects into.

Emerging players

  • Aria Pharmaceuticals: AI-driven drug discovery company focused on complex diseases using causal machine learning. Comparable to Pharos as a smaller, emerging AI drug discovery platform pursuing pharma partnerships and targeting intractable therapeutic areas.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights5 records

Customer concentration

Pharos iBio Co. social profiles

Digital presence

Pharos iBio Co. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pharos iBio Co. leadership team

Management profile

Number of profiles

Pharos iBio Co. funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pharos iBio Co. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharos iBio Co.

What does Pharos iBio Co. do?

Pharos iBio is a pharmaceutical company that develops drugs for intractable diseases using its proprietary Chemiverse AI platform, which combines in-house drug development expertise with AI/ML predictive systems. The company delivers AI-powered new drug development services and collaborates with global pharmaceutical firms to validate drug candidates and accelerate discovery timelines.

Is Pharos iBio Co. a public or private company?

Pharos iBio Co. is a private company. It is classified as public and is currently operating.

When was Pharos iBio Co. founded?

Pharos iBio Co. was founded in 2016. It employs 1 to 10 people.

Where is Pharos iBio Co. based?

Pharos iBio Co. is headquartered in Anyang, South Korea, in the Asia region.

How does Pharos iBio Co. make money?

Two revenue lines are on record. AI Drug Development Services are the primary driver. The others are platform Collaboration Licensing.

Who are Pharos iBio Co.'s main competitors?

Direct peers on record are Insilico Medicine, Recursion Pharmaceuticals, Schrödinger, Exscientia, XtalPi, Atomwise, BenevolentAI and Isomorphic Labs. Eli Lilly is listed as a broad incumbent. Aria Pharmaceuticals is listed as an emerging player.

Does Pharos iBio Co. have an API?

No public API is recorded for Pharos iBio Co..

What industry is Pharos iBio Co. in?

Pharos iBio Co.'s product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Venturesquare파로스아이바이오, 호주를 AI 신약개발 R&D 거점으로…공동연구·사업개발 확대Pharos I-Bio, an AI-based drug discovery company, presented its AI drug development platform and global collaboration strategy at a Korea-Australia symposium in Sydney. The company, which established an Australian subsidiary in 2019, is expanding joint research and business development with local institutions, including a recent agreement with Kolon Pharmaceutical for PHI-701.VenturesquareThe AI platform 'Chemiverse' has been successful... Paros I-Bio has been selected for national projects consecutively.Pharos I-Bio and Jacktus Onco were selected for a 2026 AI-based drug discovery project under the Ministry of SMEs and Startups. The project, with a total budget of 100 million won, allocates 400 million won to Pharos I-Bio for candidate design and optimization. The two companies will develop IRP2 inhibitor candidates over 24 months, targeting colorectal cancer initially.BiggoPharos iBio Joins Eli Lilly's 'TuneLab' — Accelerates Drug Discovery via Nvidia's AI Platform — BigGo FinanceSouth Korean AI-driven drug discovery firm Pharos iBio has joined Eli Lilly's 'Lilly TuneLab' platform as a strategic partner, leveraging Nvidia's federated learning technology to validate its pipeline against global standards. The collaboration aims to accelerate the development of key assets, particularly the acute myeloid leukemia treatment lasmotinib, by combining Pharos iBio's proprietary Chemiverse platform with Eli Lilly's extensive research data and AI models. This partnership is viewed as a potential commercialization pipeline that could lead to future investments, joint research, or technology transfers between the two entities.ChosunbizPharos iBio's PHI-101 receives European orphan drug status for leukemia treatmentPharos iBio announced that its AML drug candidate PHI-101 received European orphan drug designation from the EMA. The company expects reduced review periods, clinical trial consultations, and a 10-year market exclusivity period. PHI-101 was previously designated orphan by the FDA in 2019 and by Korea last year.One of the top universities in AustraliaAI drug discovery will power collaboration with Pharos TherapeuticsThe University of Sydney signed an MoU with Pharos Therapeutics to use AI for drug discovery targeting cancers and rare diseases. The partnership grants access to Pharos's Chemiverse platform, which incorporates 230 million data points and supports about 10 pipeline projects, including PHI-101 in phase 1b trials.NatureThe Chemiverse platform: AI and big data-based drug discovery and developmentPharos iBio's Chemiverse AI platform accelerates drug discovery, with its first drug PHI-101 in phase 1 trials for AML and ovarian cancer. The company has 8 ongoing programs and plans trials for triple-negative breast cancer next year.